New hope for painful skin condition: drug trial launches
NCT ID NCT07492251
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called upadacitinib for people with severe forms of lichen planus, a skin disease causing painful mouth sores or hair loss. About 56 adults will receive either the drug or a placebo for 16 weeks to see if it reduces symptoms. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EROSIVE MUCOSAL LICHEN PLANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP
Paris, France
-
CHU de Nice
Nice, Alpes Maritimes, 06200, France
-
CHU de Rouen
Rouen, France
-
CHU de Tours
Tours, France
-
Centre privé de Dermatologie
Reims, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.